An Open-label Phase I Study to Evaluate the Safety, Tolerability and Biodegradation Period of PolyActiva PA5108 Ocular Implant When Administered Intracamerally to the Anterior Chamber of the Eye
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 23 Jul 2019
Price : $35 *
At a glance
- Drugs PA-5108 (Primary)
- Indications Open-angle glaucoma
- Focus Adverse reactions
- Sponsors PolyActiva
- 23 Jul 2019 According to a PolyActiva media release, recruitment has been completed and the initial data is expected in Jan 2020.
- 23 Jul 2019 Status changed from recruiting to active, no longer recruiting, according to a PolyActiva media release.
- 10 Jul 2019 Accrual to date is 7.